Immatics N.V. — Company profile
Healthcare · Biotechnology · Germany
Last price 7.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 984.17M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna’s PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Details
| Name | Immatics N.V. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 704 |
| Ceo | Harpreet Singh |
| Country | Germany |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| Isin | NL0015285941 |
| Cusip | N44445109 |
| Cik | 1809196 |
| Sic | 2836 |
Key executives
| Name | Title |
|---|---|
| Dr. Harpreet Singh Ph.D. | Chief Executive Officer, MD, Member of Management Board and Executive Director |
| Dr. Venkat Ramanan Ph.D. | Chief Financial Officer |
| Amie Krause | Chief People Officer |
| Dr. Hans-Georg Rammensee Ph.D. | Co-Founder and Member of the Scientific Advisory Board |
| Dr. Toni Weinschenk Ph.D. | Co-Founder and Chief Innovation Officer |
| Steffen Walter Ph.D. | Chief Operations Officer |
| Ephraim Hofsäß M.Sc. | Vice President of SEC Reporting and Accounting |
| James Pepin J.D. | General Counsel and Corporate Secretary |
| Lauren Schroeder | Vice President of Marketing |
| Dr. Carsten Reinhardt M.D., Ph.D. | Chief Development Officer |
Contact
| Address | Paul-Ehrlich-Strasse 15-19, Tübingen, 72076, Germany |
| Phone | 49 7071 5397 0 |
| Website | https://www.immatics.com |